Fig 1.
2D structures of HIV-1 inhibitors previously published.
Fig 2.
Synthesis of aldehyde 6 and derivatives 9a-f.
Synthesis scheme of aldehyde 6: i) Pd(PPh3)2Cl2, Na2CO3, DMF/EtOH, RT, 1h; ii) 1N NaOH (aq), MeOH/THF, reflux 2h. Synthesis scheme of derivatives 9a-f: iii) DME, Et3N, MW (300 W), 90°C, 10 min. iv) aldehyde 6, MW (300 W), 110°C, 5 min.
Fig 3.
Antiviral activity of the novel series of rhodanine derivatives on TZM-bl cell line infected with two laboratory strains (NL4.3 and AD8).
Maraviroc (MAR) and raltegavir (RAL) were used as reference compounds. Values represent mean±S.D of three independent experiments. Differences between pre-incubation in complete medium containing FBS are shown, together with the corresponding fold change (ratio). EC50 = Half maximal effective concentration. CC50 = Half maximal cytotoxic concentration. apre-incubation in complete medium containing fetal bovine serum (FBS).
Table 1.
CC50 and EC50 values of the reference compound 2 and the control drug raltegravir (RAL) on human CD4+ T lymphocytes.
Table 2.
Antiviral activity of the rhodanine derivatives on Vero cell line infected with HSV-2.
Table 3.
Antiviral activity of compound 2 on Vero cell line infected with HSV-1, HSV-2 with serum and HSV-2 acyclovir resistant strains.
Fig 4.
Effect of different concentrations of fetal bovine serum (0%, 2%, 5% and 10%) on the antiviral activity of compound 2.
Compound 2 was tested in TZM-bl cells infected with AD8 HIV-1 laboratory strain.
Fig 5.
Effect of different concentrations of purified bovine serum albumin on the antiviral activity of compound 2 and maraviroc.
Compounds were tested on TZM-bl cells infected with AD8 HIV-1 strain. No BSA = absence of BSA; 1X = 35 mg/mL BSA; 5X = 175 mg/mL BSA; 10X = 350 mg/mL BSA.
Fig 6.
Anti-HIV-1 activity of compound 2 (black line) and tenofovir (T, grey line) in gel, formulation, in human TZM-bl cell line.
Each concentration of both compounds was evaluated in triplicate.
Table 4.
Results of in vitro ADME analysis for selected rhodanine derivatives.